The Clorox Company $CLX Shares Purchased by Willis Investment Counsel

Willis Investment Counsel grew its stake in The Clorox Company (NYSE:CLX) by 4.3% during the 3rd quarter, Holdings Channel reports. The fund owned 232,400 shares of the company’s stock after acquiring an additional 9,494 shares during the period. Clorox comprises about 1.6% of Willis Investment Counsel’s portfolio, making the stock its 22nd biggest position. Willis Investment Counsel’s holdings in Clorox were worth $28,655,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in CLX. Nomura Asset Management Co. Ltd. raised its stake in Clorox by 9.0% during the 2nd quarter. Nomura Asset Management Co. Ltd. now owns 335,514 shares of the company’s stock valued at $40,285,000 after acquiring an additional 27,639 shares in the last quarter. Hudson Bay Capital Management LP acquired a new position in shares of Clorox during the second quarter valued at $8,568,000. Vanguard Personalized Indexing Management LLC raised its stake in shares of Clorox by 64.2% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 25,732 shares of the company’s stock valued at $3,173,000 after purchasing an additional 10,065 shares in the last quarter. Vise Technologies Inc. acquired a new stake in Clorox in the second quarter worth about $328,000. Finally, Brookstone Capital Management grew its position in Clorox by 1,395.4% in the 3rd quarter. Brookstone Capital Management now owns 94,332 shares of the company’s stock valued at $11,631,000 after buying an additional 88,024 shares in the last quarter. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox News Summary

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Morgan Stanley raised its price target to $136 and kept an “equal weight” rating, highlighting upside vs. the current share level. Clorox (NYSE:CLX) Price Target Raised to $136.00 at Morgan Stanley
• Positive Sentiment: Jefferies trimmed its target to $151 but maintained a “buy” rating, signaling continued conviction in the longer-term upside (large percentage upside remains). Jefferies Adjusts Clorox Price Target to $151
• Neutral Sentiment: Clorox will present at the CAGNY conference Feb. 19; management access may provide additional color for investors but is not an immediate earnings driver. Clorox to Present at 2026 CAGNY Conference
• Neutral Sentiment: Company is weighing a potential GOJO deal and completing an ERP integration — strategic moves that could boost long-term positioning but are creating near-term execution/cost uncertainty. Clorox Weighs GOJO Deal And ERP Finish Against Softer Earnings
• Neutral Sentiment: JPMorgan nudged its target to $117 and kept a neutral rating — a minimal change that signals little near-term conviction from that shop. JPMorgan Adjusts Clorox PT to $117
• Neutral Sentiment: TD Cowen raised its target slightly to $111 and maintained a “hold”, a modest signal relative to other shops. TD Cowen Adjusts Clorox Price Target to $111
• Negative Sentiment: Brokerage consensus across several shops shows a tilt toward downgrade/reduction in enthusiasm (a published “Reduce” consensus was flagged), which increases selling pressure. The Clorox Company (NYSE:CLX) Given Consensus Rating of “Reduce” by Brokerages
• Negative Sentiment: Q2 results were mixed: adjusted EPS missed estimates, organic sales declined year-over-year and management cited ERP/inventory pressures that are squeezing margins. Clorox Q2 Earnings Miss Estimates, Lower Organic Sales Hurt
• Negative Sentiment: Analysts warn of a near-term profit squeeze from inventory resets and integration costs, a structural headwind for margins in 2026. Clorox Faces Profit Squeeze From Inventory Reset In 2026
• Negative Sentiment: Evercore cut its target to $115 and kept an “underperform” rating, and Deutsche Bank trimmed its target to $112 — additional downward pressure from institutional sellers. Evercore Adjusts Clorox Price Target to $115

Insider Buying and Selling

In other news, Director Pierre R. Breber acquired 4,000 shares of Clorox stock in a transaction on Friday, November 21st. The shares were purchased at an average cost of $104.13 per share, for a total transaction of $416,520.00. Following the completion of the purchase, the director directly owned 13,000 shares of the company’s stock, valued at approximately $1,353,690. This represents a 44.44% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.63% of the stock is currently owned by company insiders.

Clorox Price Performance

Shares of CLX opened at $117.18 on Friday. The company’s 50-day moving average is $105.58 and its 200-day moving average is $114.01. The company has a debt-to-equity ratio of 71.03, a current ratio of 0.74 and a quick ratio of 0.50. The firm has a market capitalization of $14.17 billion, a PE ratio of 19.18, a PEG ratio of 0.57 and a beta of 0.59. The Clorox Company has a fifty-two week low of $96.66 and a fifty-two week high of $159.04.

Clorox (NYSE:CLX) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $1.39 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.04). Clorox had a net margin of 11.17% and a return on equity of 383.01%. The firm had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.64 billion. During the same period in the prior year, the company earned $1.55 earnings per share. The business’s quarterly revenue was down .8% compared to the same quarter last year. Equities analysts forecast that The Clorox Company will post 7.15 EPS for the current year.

Clorox Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Wednesday, January 28th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date is Wednesday, January 28th. Clorox’s dividend payout ratio (DPR) is 81.05%.

Wall Street Analyst Weigh In

CLX has been the topic of a number of research analyst reports. Zacks Research upgraded shares of Clorox from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. Citigroup boosted their price objective on Clorox from $109.00 to $115.00 and gave the stock a “neutral” rating in a research note on Wednesday. UBS Group raised their target price on Clorox from $115.00 to $121.00 and gave the company a “neutral” rating in a research note on Wednesday. The Goldman Sachs Group dropped their price target on shares of Clorox from $110.00 to $94.00 and set a “sell” rating on the stock in a research report on Wednesday, January 7th. Finally, Evercore ISI reduced their price objective on shares of Clorox from $132.00 to $115.00 and set an “underperform” rating for the company in a research report on Wednesday. One research analyst has rated the stock with a Buy rating, ten have assigned a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat, Clorox has a consensus rating of “Reduce” and an average target price of $117.93.

Clorox Company Profile

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.